RESEARCHER PROFILE
Dr Alex Cole (Filmed May 2024)
Research Officer
Centre for Biomedical AI,
Centenary Institute,
Sydney, Australia
Ovarian cancer, one of the deadliest cancers affecting women worldwide, is a challenging disease to treat. High rates of chemotherapy resistance hinder treatment success and patient survival.
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
“We know that chemotherapy triggers increased FST production in the body, which aids cancer cells in resisting treatment,” said Dr Cole.
“Our nanobodies, derived from antibodies and engineered to target and neutralise FST, could potentially make cancer cells vulnerable to chemotherapy again.”
Dr Cole emphasised the critical importance of developing innovative therapies like FST nanobody therapy to improve patient outcomes.
“Chemotherapy is initially highly effective in treating ovarian cancer in women. However, in over 70% of cases the cancer will reoccur, often having developed resistance to chemotherapy, rendering it ineffective,” he said.
The grant, received through Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS) is co-funded by Cancer Australia and the Ovarian Cancer Research Foundation
Dr Cole received his PhD from the University of Sydney in 2017 (Kolling Institute) where he studied the role of epigenetic histone modifications on ovarian cancer. Alex continued his ovarian cancer research investigating the role of quiescence on cancer stem cells during Postdocs at the University of Michigan and the University of Pittsburgh. During this time, he received the Ann and Sol Schreiber Mentored Investigator Award from the Ovarian Cancer Research Fund Alliance, which led to the discovery that follistatin is secreted in response to chemotherapy where it actively promotes chemoresistance.
In 2020, he joined the Directed Evolution Lab at the Centenary Institute under Associate Professor Daniel Hesselson, where he worked to develop the novel viral directed evolution platform PROTEUS (Protein Evolution Using Selection). In 2023, Alex received a Tour de Cure grant which allowed for the validation of PROTEUS for nanobody evolution.
-
Medically Complex Pregnancies
A/Prof Shelley Wilkinson is an Advanced Accredited Practising Dietitian, Fellow of Dietitians Australia, and a leading Australian researcher in maternal health and implementation science.
She has over 30 years of experience in the field and holds a PhD in Psychology. Her passion is in health service redesign through co-creation and combining the ‘know-what’ of nutrition with the ‘know-how’ of innovative behaviour change techniques.
-
CASE STUDY High blood pressure and shorter sleep may worsen brain decline
People with high blood pressure who also lack sleep may be at increased risk of reduced cognitive performance and greater brain injury, Monash University research has found.
Published in the Journal of the American Heart Association, researchers assessed whether the combined effect of hypertension and short sleep duration had a negative impact on brain health.
-
Food and fasting periods as medicine to prevent disease
Professor Leonie Heilbronn is based at the South Australian Health and Medical Research Institute (SAHMRI), where she leads the Obesity and Metabolism laboratory. Her research is at the interface between basic and clinical science. She is internationally recognised for her work in nutritional modulation in humans and has made major contributions to our current understanding of mechanisms underlying conditions such as insulin resistance, particularly inflammation and lipid metabolism. She has also contributed significantly to current concepts of caloric restriction (CR), intermittent fasting (IF) and time restricted eating (TRE) in humans. She has published more than 110 peer reviewed papers in scientific journals and is an Associate Editor of Obesity, and Obesity Research and Clinical Practice.
